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1Previous commnications by our group ,2,3 have charac­
terized the distribution of six antibacterial agents. Determining
 
the 	concentration of each antimicrobial in renal lymph was the 
unique aspect of these studies. Corresponding biological fluid 
sa.ples were obtained from plasma and urine in order to allow con­
ventional comparisons to be made. All of these experiments were 
performed in mongrel dogs. 
The 	purpose of these experiments is to report the distri­
bution of cycloserine (Seromycin) and oxytetracycline (Terranlycin)
 
in renal lymph, urine and plasma. In addition, new iata are reported 
on the lymphatic distribution of nitrofurantoin; we cow-pare con­
centrations of this antiseptic in renal hilar .lymph and cisterna
 
chyli lymph. 
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MNTLODS AID PROCEDU1MES 
Mongrel dogs were anesthetized and the lymphatics were
 
cannulated, We have previously detailed our techniques Cioterna 
chyli lymph was collected via a polyethylene cannula carefully 
inserted into a major channel. 
. Cycloserinet 53.mg/Rg, was infused intravenously as a-
bolms after obtaining baseline lymph , plasma and urinee.
 
C a.
Gloserine was analyzed by the method of Jones4

Oxytetraaycline, 48 mg/Kgt was also infused intravenously 
as a bolus. The analysis of oxyttracycline was carried out using 
a florescent tetbnigue5 . A slight modification was necessary for 
oxytetracyclino0 
Uitrofurantoint 7 mg/Kg, was administered by gastric 
tube. We have previously detailed the chemical and biological 
assay methods for this antibacterial, 
RESULTS
 
Two separate experimentscht. 
tion of cycloserine in renal lymph, plasma and urine are illus­
trated in Figures I and 2. Renal lymph levels exceed the cor­
responding plasma concentrations in almost all instances,. Similar 
patterns were seen in a total of five animals. 
The distribution of osytetracycline in renal lymphr 
plasma and urine is listed 'in tabular form (Table I). Renal lymph 
levels of oxytetraoycline exceed the corresponding plasma in the 
early post-injection periods. The lymph levels then decline to 
lesser concentrations which are equal to or less than the corres­
ponding plasma levels. Urinary levels range from several hundred 
micrograMs to levels of 40-50 micrograms several hours later. 
2itrofurantoin was assayed in renal hilar lymph and 
cisterna chyli l mph (fig. 3 and 4). Hilar lymph concentrations 
are higher than corresponding cisterna chyli lymph concentrations. 
The renal lym.ph concentrations however, are several times higher 
than the nlasma levels several hours after admin'stration of the 
drug. 
DISCUSSION 
Cyoloserine..a second choice selection in the treatment
 
of renal tubarculosis would appear to be effective on the basis 
oz it's interstitial concentrations. After obtaining baseline 
lsh, plasma and urine, cycloserine (50 mg/Kg) was infused intra­
venously as a bolus. Our data suggests that cycloserine may well 
be the most effective agent in treating renal tuberculosis. 
Selected proteus and aerobactor infections causing inter­
stitial pyelonephritis may also respond to cycloserine providing
 
tube dilution sensitivity studies are%performed. 
Oxytetracycline, 
-an antibiotic with effective urinary
 
concentrations when'given as prescribed, appears to passively 
diffuse into renal lymph. Renal lymph levels exceed the relatively 
low corresponding plasma levels several hours after injection and 
may account for it's effectiveness in selected cases. Still
 
-4­
underway in our laboratory are studies to evaluate the effects
 
of protein binding on the family of tetracyclines. While still
 
conjectural, it is possible that drugs which exist in higher free
 
concentrations, while unbound to proteino may more easily diffuse
 
into the renal interstitium.
 
Nitrofurantoin, the first antiseptic we demonstrated to 
concentrate in renal lymph, was administered in several animals. 
Hilar lymph levels exceed the cisterna chyli levels in dogs. 
Hilar-levels up to 6 mcg/~m were obtained, Plasma levels are 
quite reduced. 
We believe that these studies which plot the distribu­
tion of antibiotics in-various body compartments or tissue spaces 
are important 
. 
Clinical applications might be made based on the 
needs of selected tissue compartments. In pyalonperitis renal
 
lymph concentrations are highly important. Antibiotic selection
 
should be based on the drug's distribution in renal lymph. For
 
urinary stasis with subsequent infection, an antimicrobial which
 
has high urinary concentrations would be the agent of choice.
 
when considering treatment for pyelonephritis, high blood levels,
 
while important for any antibiotic, should not remain the primary
 
requisite.
 
TABLE I
 
DOG # TIME 
in 
HOURS 
12531 0 
1 
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3 
4 
5 
14 0 0 
1 
2 
3 
A 
5 
1458 0 
1 
2 
3 
4 
5 
OXYTETRACYCLINE 

LYI-J H mcq/t 
0 
154-
10.6 

5.8 
3.8 
3.5 
0 
32.9 
9.1 
8.1 
8.5 
6.8 
0 
19.0 
9.4 
72. 
5.6 
5.3 
IN 'PENAL LYMPH
 
PLASMA mcg/i URINE mcg/ml 
0 0 
12.4 85 
11.6 130 
7.8 50 
5.8 50 
5.6 
0 0 
12.7 440 
9.4 90 
15.4 105 
14.9 140 
8.6 100 
0 0 
10.4 145 
ll.6 425 
61. 110 
6.3 60 
5.6 40 
4.6 
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FigUre 1. Distribution of cycloserine in renal lymph, plasma 
and urine. 
Figure 2o Second experiment. Dishribution of cycloserine in 
renal lymph, p~asma and urine. 
Figure 3. Distribution of nitrofurantoin in hilar lymph, cisterna 
chyli lymph and plasma. 
Figure 4. Second-experiment. Distribution of nitrofurantoin in. 
hilar lyaph cisterna dhyli lymph and plasma. 
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